Spots Global Cancer Trial Database for A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
Official Title: A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Study ID: NCT01677390
Conditions
Study Description
Brief Summary: This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stanford Cancer Center, Stanford, California, United States
Rocky Mountain Cancer Centers - Midtown, Denver, Colorado, United States
Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill, North Carolina, United States
Miriam Hospital, The, Providence, Rhode Island, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Seattle Cancer Care Alliance / University of Washington, Seattle, Washington, United States
Contact Details
Name: Elaina Gartner, MD
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
